Columbia neuroscientists have identified a genetic mutation that fends off Alzheimer's in people at high risk and could lead to a new way to protect people from the disease.
With funding from the Ultra-rare Gene-based Therapy Network, scientists at Columbia and the n-Lorem Foundation will create tailor-made gene-based therapies for people with rare forms of ALS.
A study led by Columbia and Cornell researchers finds, surprisingly, that anticoagulants do not prevent recurrent strokes in people with one type of heart condition.
Four research centers including the Center for Stroke Disparities Solutions—a partnership of the New York University Langone Medical Center and Columbia University Medical Center —will develop high-impact culturally tailored interventions aimed at lowering stroke risk among racial and ethnic minorities in the United States.
African-Americans carrying a variant in a cholesterol-processing gene, ABCA7, have double the risk for Alzheimer’s than non-carriers. A new study led by CUMC's Richard Mayeux; first author Christiane Reitz.
African-Americans with Alzheimer’s disease were slightly more likely to have one gene, ABCA7, that is thought to confer risk for the disease. CUMC's Dr. Richard Mayeux led the study.
The largest genome-wide search for Alzheimer’s genes in African-Americans has found that African-Americans with a variant of the ABCA7 gene have almost double the risk of developing late-onset Alzheimer’s disease.
CUMC's Dr. Eric Kandel (2000 Nobel Laureate) said the project may lead to an understanding of "who we are as human beings and how we function and how these terrible diseases arise, and what we might be able to do address them more effectively."
New evidence that chronic infection, known to be associated with vascular disease, is also associated with poorer performance on tests of mental ability.
Viruses and bacteria can trigger inflammation in blood vessels throughout the body, including the brain, said study author Dr. Mira Katan with CUMC's Northern Manhattan Study.